Chemotherapy is epithelial ovarian cancer assisted the main method of treatment. Chemotherapy can significantly improve the control rate of ovarian extension of survival time without the role has been affirmed. Epithelial ovarian cancer Ⅰ A and B Phase I, if poor cell differentiation, adhesion obvious lesions, and epithelial ovarian cancer Phase 1 C, the need for post-surgical adjuvant treatment. Random The results showed that radionuclide 32P abdominal radiotherapy in the treatment of patients with survival rate after chemotherapy of cisplatin and the survival rates similar, but 32P abdominal radiotherapy complications higher. II adjuvant therapy after surgery, residual focus primarily on the basis of the size of a decision. Postoperative residual lesions <2 cm choice adjuvant therapy, chemotherapy commonly used programs: programs such as TP (Taxol cisplatin), CP program (cyclophosphamide cisplatin), CC program (cyclophosphamide carboplatin); If the gross residual disease without abdominal and pelvic lesions residues < 0.5 cm, with full and total abdominal pelvic radiotherapy. Postoperative residual lesions> 2 cm, the main choice of adjuvant therapy TP, CP, or combined with chemotherapy in the treatment of CC. Ⅲ eliminate ovarian cancer by surgery, to give the intraperitoneal cisplatin-based chemotherapy or systemic chemotherapy in patients with prolonged median survival time. Postoperative intraperitoneal adhesions obvious it is not appropriate for patients with intraperitoneal chemotherapy. GOG a randomized controlled study showed that, by not eliminate ideals of the Phase III and IV ovarian cancer to chemotherapy or TP CP chemotherapy, respectively 73% and 60%, surgery confirmed the complete remission rates were 26% and 20%, the median survival time was 38 months and 24 months, both the efficiency of chemotherapy and survival time difference was significant (P <0.001). Europe and Canada both chemotherapy-control study showed that, with the TP Taxol chemotherapy patients without relapse rate and overall survival rate was significantly better than non-CP Taxol chemotherapy group. Ongoing research includes Taxol intraperitoneal chemotherapy, autologous bone marrow transplantation high-dose chemotherapy.
Tags:
cell,
grams,
lesions,
patient,
patients,
radiotherapy,
surgery,
treatment